Anti-Human PCSK9 Antibody (SAA0158)

Anti-Human PCSK9 Antibody (SAA0158)

  • Catalog number: FC10055
  • Availability: In Stock
  • $191.00

  • Ex Tax: $191.00


Available Options

Qty
  • Description: Anti-Human PCSK9 Antibody (SAA0158) [SAA0158] (FC10055) is a human monoclonal antibody detecting PCSK9 in FCM. Suitable for Human.
    Highlights:
    • Flow Cytometry — Validated for flow cytometry applications.
  • Model: HV275107
  • Name: Anti-Human PCSK9 Antibody (SAA0158)
  • Host species: Human
  • Isotype: IgG2, lambda
  • Conjugation: Unconjugated
  • Species reactivity: Human
  • Form: Liquid
  • Storage buffer: 0.01M PBS, pH 7.4.
  • Concentration: 2.18 mg/ml
  • Purity: >95% as determined by SDS-PAGE.
  • Clonality: Monoclonal
  • Applications: FCM
  • Target: Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
  • Purification: Protein A/G purified from cell culture supernatant.
  • Endotoxin level: Please contact with the lab for this information.
  • Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
  • Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha).
    References:
    1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658
    2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796
    3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702
    4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458
    5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827
    6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
  • Note: For research use only.

Images

  • SDS-PAGE for Anti-Human PCSK9 Antibody (SAA0158)
    SDS-PAGE

    SDS-PAGE for Anti-Human PCSK9 Antibody (SAA0158)

Be the first to write a review for this product.

Write a review

Note: HTML is not translated!
Bad           Good